Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07569159 · ClinicalTrials.gov registry record · Phase 2
MDMA Therapy in Veterans With PTSD
A Phase 2 study, sponsored by Sunstone Medical.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT07569159 is a Phase 2 study that is actively recruiting participants, run by Sunstone Medical. The registered enrollment target is 52 participants.
The verdict
NCT07569159, a Phase 2 study, is actively recruiting participants, sponsored by Sunstone Medical.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
A Phase 2, single-center, fixed-dose, open-label study will explore the efficacy, safety, and tolerability of a 120 mg dose of oral MDMA followed by a supplemental dose of 60 mg MDMA in conjunction with therapy in individual versus group settings for adult veterans diagnosed with PTSD.
Interventions
- DRUG MDMA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2026-06-30 |
| Est. Completion | 2027-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07569159
The ClinicalTrials.gov registry entry for NCT07569159 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sunstone Medical, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MDMA is the first listed.
NCT07569159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07569159 about?
NCT07569159 is a clinical study titled "MDMA Therapy in Veterans With PTSD". A Phase 2, single-center, fixed-dose, open-label study will explore the efficacy, safety, and tolerability of a 120 mg dose of oral MDMA followed by a supplemental dose of 60 mg MDMA in conjunction with therapy in individual versus group settings for adult veterans diagnosed with PTSD.
What is the current status of trial NCT07569159?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2026-06-30. Estimated completion is 2027-08.
What interventions are being tested in trial NCT07569159?
The interventions under investigation include: MDMA (DRUG).
Who is sponsoring clinical trial NCT07569159?
This trial is sponsored by Sunstone Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.